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ticular, only 5 of the 19 sexuality/ED-specific measures
adequately covered the conceptual domains of interest
while only 8 of them had adequate evidence of reliability,
validity and responsiveness. CONCLUSION: Our review
underscores the need for a careful examination of pub-
lished psychometric properties of instruments that are be-
ing considered for use even when they are claimed to
have been developed for persons with ED and related
sexual disorders.
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As the female population continues to live longer past
menopause, healthcare providers need to establish a pro-
active approach to the management of the menopausal
population in order to reduce long-term healthcare ex-
penditures. OBJECTIVE: The purpose of this analysis is
to assess the cost-effectiveness of hormone replacement
therapy (HRT) in peri-menopausal women of Belgium
and the United Kingdom. METHODS: A Markov model
was constructed to model treatment pathways and out-
comes of two cohorts. The model compares the health
and economic outcomes of women from age 53 through
94 treated with HRT versus those not treated with HRT.
The following “health states” were considered in the
model: well, osteoporosis-related fractures, coronary
heart disease, stroke, Alzheimer’s disease, breast cancer,
diabetes and death. A clinical management analysis de-
termined health care utilization for each “health state”,
while published epidemiologic estimates from each coun-
try, incorporating relative risk ratios, incidence and mor-
tality rates for each “health state” were entered into the
model. A resource valuation using country-specific inpa-
tient and outpatient costs were calculated for each
“health state”. RESULTS: Cost-effectiveness was mea-
sured as the incremental cost-per-life-year gained and the
incremental cost per event avoided. Assuming full com-
pliance with treatment in the HRT cohorts, the results
for Belgium and the United Kingdom indicate significant
reductions in episodes of disease. Furthermore, lifetime
expected costs per patient in the treated cohort decreased
with age while the lifetime costs of the untreated cohort
increased with age. A Monte Carlo analysis tested the
sensitivity of the model results. CONCLUSIONS: Hor-
mone replacement therapy is a more cost-effective means
of disease prevention when compared to no treatment
and should be considered by healthcare providers in Bel-
gium and the United Kingdom in the health management
of peri-menopausal populations.
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Benign Prostatic Hyperplasia (BPH) is common among
males in the Veterans Administration (VA) population.
The quality of life of such patients can decline signifi-
cantly since symptoms may interrupt normal daytime ac-
tivities or sleep, create anxiety, or reduce perception of
general health. Though clinical practice guidelines for the
management of BPH have been established, little research
has been done to determine adherence to such guidelines.
OBJECTIVE: To determine the preferences of urologists
in the management of BPH in the VA population to as-
sess compliance with established guidelines. METHODS:
A self-administered mail survey was sent to about 300
urologists providing services to the VA population in ap-
proximately 145 VA medical centers across the US. The
survey contained simulated cases of BPH patients, to de-
termine urologists’ preferences for diagnostic tests and
treatments recommended in the management of BPH.
The survey also gathered information on frequency of
failed initiation therapy and demographic and practice
information. The survey was pilot tested for face and
content validity among 10 urology residents. Descriptive
statistics will be used to analyze the level of agreement
among respondent urologists for diagnostic procedures
and treatments recommended. Differences based on de-
mographic and practice characteristics will also be deter-
mined. Urologists’ preferences will also be compared
with clinical guidelines and responses of an expert panel.
Failure rates for initiation therapy will also be deter-
mined using descriptive statistics. Published cost data for
various diagnostic procedures will be used to estimate the
mean cost of diagnosing BPH in the VA population.
CONCLUSION: Study results will help us better under-
stand how BPH is managed in the VA population.
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OBJECTIVES: This research investigates the use of longi-
tudinal/cohort observational designs containing patient-
specific data for the economic evaluation of pharmaceuti-
cals in development or on the market, and appraises the
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value of such observational datasets, relative to the con-
struction or use of RCT study designs. METHODS: A
systematic review of a health economics literature data-
base (HEED) was conducted to explore the use of obser-
vational and RCT data in applied pharmacoeconomic
evaluations in the UK (1990–1999). A comparative anal-
ysis of longitudinal datasets (containing resource use and
outcomes data) developed in the UK (e.g. DIN-LINK,
GPRD) was undertaken with an assessment of the poten-
tial analytical approaches (multivariate techniques, cross-
design synthesis) and methodological and practical con-
siderations. RESULTS: A total of 71 studies were identi-
fied, 59 CEAs only, 6 CUAs only and 6 where both CEAs
and CUAs were conducted. The table presents the type of
data used in these studies for the three core data items of
a pharmacoeconomic evaluation. RCT data represented
the majority source for all three items, in particular for
clinical event and disease outcome data. Observational
data sources were more frequently used to provide re-
source use consequence data. None of the reviewed stud-
ies made use of any existing prospective or retrospective
database. CONCLUSIONS: Regardless of the system of
health care, there is an obvious and universal need for re-
liable data on the effectiveness and costs of clinical inter-
ventions. Observational datasets have implications for
outcomes research conducted in pharmaceutical compa-
nies. There is little literature on the use of observational
data in economic evaluation, and more debate on this
subject is needed. As we gain a better understanding of
the tradeoffs between internal and external validity, it is
predicted that more pharmacoeconomic analyses will in-
creasingly be based on observational data or a combina-
tion of observational and RCT data.
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Data source
Observational RCT
Resource use consequences 21 27
Clinical events 19 37
Disease outcomes 19 33
All 3 sets of core data 9 14
Core data for economic evaluations
Data source
Observational 
& RCT Other
Resource use consequences 3 20
Clinical events 6 9
Disease outcomes 6 13
All 3 sets of core data 1 6
OBJECTIVES: To evaluate the accuracy of claims versus
original prescriptions by calculating the match rate for 7
fields: drug, strength, dosage form, quantity, day’s sup-
ply, daily dose, and date dispensed. Claims accuracy was
also analyzed by therapeutic class for antibiotics, oral hy-
poglycemics, H2 antagonists, antipsychotics, and antide-
pressants. METHODS: Purdue’s Pharmaceutical Eco-
nomics Research Center (PERC) systematically recruited
10 pharmacies from a random list generated by phar-
macy benefits manager PCS Health Systems, Inc. (PCS).
PCS randomly extracted 500 claims submitted by each
pharmacy between 07/01/96 and 06/30/97. Pharmacies
obscured patient information and photocopied the origi-
nal prescriptions. Trained assistants abstracted 5 fields
and calculated day’s supply and daily dose from the di-
rections for use. RESULTS: Six of 10 pharmacies pro-
vided 2,938 photocopies, split approximately evenly
among therapeutic classes. Overall match rates were:
drug (99.9%), strength (97.0%), dosage form (95.5%),
quantity (94.1%), day’s supply (85.2%), daily dose
(83.2%), and date dispensed (65.1%). Applicable mean
percentage differences were: strength (1.32%), daily dose
(2.53%), day’s supply (2.73%), and quantity (6.03%).
The mean difference for date dispensed was 19.3 days.
Match rates were comparable for antidepressants, anti-
psychotics, and H2 antagonists. Antibiotic and oral hy-
poglycemic rates were more variable. CONCLUSIONS:
Claims reliability was excellent for drug, strength, dosage
form, and quantity and good for day’s supply and daily
dose. Antidepressant, antipsychotic, and H2 antagonist
classes had comparable reliability. The reliability of date
dispensed appeared questionable, but the dates recorded
by hand on prescriptions were later than those automati-
cally submitted for claims, suggesting that claims data
may be more accurate than the original prescriptions.
This study found prescription claims to be a reliable data
source for health care research.
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When conducting economic analyses using administra-
tive claims, it is important to account for the impact of
comorbidities on healthcare costs. The Chronic Disease
Score (CDS) is a useful risk-adjustment tool for use in
pharmacy claims-based research, however the published
version does not include important new drugs and the
weights were developed from smaller, geographically re-
stricted databases. OBJECTIVES: The purpose of this
study is to: (1) update the number and types of drugs in-
cluded in the CDS (2) develop new weights based on a
large, multi-region pharmacy claims database, and (3)
evaluate the revised CDS in explaining variations in and
predicting drug expenditures. METHODS: Analyses
